Patents by Inventor Peter Choyke
Peter Choyke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101685Abstract: Provided herein are methods of treating a subject with cancer using a therapeutically effective amount of one or more one or more tumor-specific antibody-IR700 molecules. The methods can further include administering to the subject a therapeutically effective amount of (a) one or more CTLA4 antibody-IR700 molecules, one or more PD-L1 antibody-IR700 molecules, or combinations thereof, (b) one or more reducing agents, (c) one or more immunoactivators, or combinations of a, b, and c, for example, either simultaneously or substantially simultaneously with the tumor-specific antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The method also includes irradiating the subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2. The use of one or more reducing agents can reduce edema resulting from treatment.Type: ApplicationFiled: January 28, 2022Publication date: March 28, 2024Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 11781955Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: September 21, 2020Date of Patent: October 10, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Publication number: 20230050584Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: June 15, 2022Publication date: February 16, 2023Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20220288210Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: May 17, 2022Publication date: September 15, 2022Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 11364297Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: November 25, 2019Date of Patent: June 21, 2022Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 11364298Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: November 26, 2019Date of Patent: June 21, 2022Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 11200667Abstract: Disclosed prostate computer aided diagnosis (CAD) systems employ a Random Forest classifier to detect prostate cancer. System classify individual pixels inside the prostate as potential sites of cancer using a combination of spatial, intensity and texture features extracted from three sequences. The Random Forest training considers instance-level weighting for equal treatment of small and large cancerous lesions and small and large prostate backgrounds. Two other approaches are based on an AutoContext pipeline intended to make better use of sequence-specific patterns. Also disclosed are methods and systems for accurate automatic segmentation of the prostate in MRI. Methods can include both patch-based and holistic (image-to-image) deep learning methods for segmentation of the prostate. A patch-based convolutional network aims to refine the prostate contour given an initialization. A method for end- to-end prostate segmentation integrates holistically nested edge detection with fully convolutional networks.Type: GrantFiled: February 22, 2018Date of Patent: December 14, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nathan S. Lay, Yohannes Tsehay, Ronald M. Summers, Baris Turkbey, Matthew Greer, Ruida Cheng, Holger Roth, Matthew J. McAuliffe, Sonia Gaur, Francesca Mertan, Peter Choyke
-
Patent number: 11013803Abstract: It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm?2.Type: GrantFiled: August 2, 2016Date of Patent: May 25, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Kazuhide Sato, Noriko Sato
-
Publication number: 20210079112Abstract: Provided herein are methods of treating a subject with cancer with a combination of antibody-IR700 molecules and immunomodulators. In particular examples, the methods include administering to a subject with cancer a therapeutically effective amount of one or more antibody-IR700 molecules, where the antibody specifically binds to a cancer cell surface protein, such as a tumor-specific antigen. The methods also include administering to the subject a therapeutically effective amount of one or more immunomodulators (such as an immune system activator or an inhibitor of immuno-suppressor cells), either simultaneously or substantially simultaneously with the antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) are then irradiated at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2.Type: ApplicationFiled: April 9, 2019Publication date: March 18, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human SerInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20210010914Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: ApplicationFiled: September 21, 2020Publication date: January 14, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Patent number: 10830678Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: August 7, 2015Date of Patent: November 10, 2020Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Publication number: 20200095331Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: November 26, 2019Publication date: March 26, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20200085950Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: November 25, 2019Publication date: March 19, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 10538590Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: August 21, 2013Date of Patent: January 21, 2020Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 10537641Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: September 28, 2015Date of Patent: January 21, 2020Assignee: The USA as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20190370965Abstract: Disclosed prostate computer aided diagnosis (CAD) systems employ a Random Forest classifier to detect prostate cancer. System classify individual pixels inside the prostate as potential sites of cancer using a combination of spatial, intensity and texture features extracted from three sequences. The Random Forest training considers instance-level weighting for equal treatment of small and large cancerous lesions and small and large prostate backgrounds. Two other approaches are based on an AutoContext pipeline intended to make better use of sequence-specific patterns. Also disclosed are methods and systems for accurate automatic segmentation of the prostate in MRI. Methods can include both patch-based and holistic (image-to-image) deep learning methods for segmentation of the prostate. A patch-based convolutional network aims to refine the prostate contour given an initialization. A method for end- to-end prostate segmentation integrates holistically nested edge detection with fully convolutional networks.Type: ApplicationFiled: February 22, 2018Publication date: December 5, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Nathan S. Lay, Yohannes Tsehay, Ronald M. Summers, Baris Turkbey, Matthew Greer, Ruida Cheng, Holger Roth, Matthew J. McAuliffe, Sonia Gaur, Francesca Mertan, Peter Choyke
-
Publication number: 20180236076Abstract: It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm?2.Type: ApplicationFiled: August 2, 2016Publication date: August 23, 2018Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human, ServicesInventors: Hisataka Kobayashi, Peter Choyke, Kazuhide Sato, Noriko Sato
-
Publication number: 20170122853Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: ApplicationFiled: August 7, 2015Publication date: May 4, 2017Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Publication number: 20160256564Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: September 28, 2015Publication date: September 8, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 9358306Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: June 27, 2012Date of Patent: June 7, 2016Assignee: The United States of America, as rep. by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo